

Cystic Fibrosis Gene Therapy: Methods for the optimisation of CFTR gene delivery.

By Karlea Lee Kremer

Discipline of Paediatrics

School of Paediatrics and Reproductive Health

Faculty of Health Sciences

The University of Adelaide

Submitted April 2010

11

References

1. Welsh, M.J., et al., *Cystic Fibrosis*, in *The Metabolic and Molecular Basis of Inherited Disease*. 1995, McGraw Hill. p. 3799-3876.
2. Schmidt, J.G., *Book of Folk Philosophy*. 1729.
3. Landsteiner, K., *Darmverschluss durch eingedicktes Meconium Pankreatitis*. Zentrabl Allg Pathol, 1905. **16**: p. 903.
4. Anderson, D.H., *Cystic Fibrosis of the pancreas and its relation to celiac disease: Clinical and pathological study*. Am. J. Dis. Child, 1938. **56**: p. 344.
5. Farber, S., *Some organic digestive disturbances in early life*. J. Mich. State. Med. Soc., 1945. **44**: p. 587-594.
6. Riordan, J., J. Rommens, and B. Kerem, *Identification of the cystic fibrosis gene: cloning and characterisation of complementary DNA*. Science, 1989. **245**: p. 1066-1073.
7. Engelhardt, J.F., et al., *Submucosal glands are the predominant site of CFTR expression in the human bronchus*. Nat. Genet., 1992. **2**: p. 240.
8. Rich, D.P., et al., *Expression of cystic fibrosis transmembrane conductance regulator corrects defective chloride channel regulation in cystic fibrosis airway epithelial cells*. Nature, 1990. **347**: p. 358-363.
9. Bear, C.E., et al., *Purification and functional reconstitution of the cystic fibrosis transmembrane conductance regulator (CFTR)*. Cell, 1992. **68**: p. 809-818.
10. Sheppard, D.N. and M.J. Welsh, *Structure and function of the CFTR chloride channel*. Physiological Reviews, 1999. **79**(1): p. S23-S45.
11. Bargon, K., et al., *Down regulation of cystic fibrosis transmembrane conductance regulator gene expression by agents that modulate intracellular divalent cations*. Mol. Cell Biol., 1992. **12**: p. 1872.
12. Bescanon, F., et al., *IFN- γ down regulates CFTR gene expression in epithelial cells*. Cell Physiology, 1994. **267**(5): p. c1398-1405.
13. Reddy, M., M. Light, and P. Quinton, *Activation of the epithelial Na⁺ channel (ENaC) requires CFTR Cl⁻ channel function*. Nature, 1999. **402**(759): p. 301-304.
14. Quinton, P.M., *The neglected ion: HCO₃⁻*. Nature Medicine, 2001. **7**(3): p. 292-293.
15. Riordan, J., *CFTR Function and Prospects for Therapy*. Annual Review of Biochemistry, 2008. **77**: p. 701-726.
16. *Cystic Fibrosis Mutation Database*, 02 March 2007, retrieved May 2009, <http://www.genet.sickkids.on.ca/cftr>.

17. Boucher, R.C., *An overview of the pathogenesis of cystic fibrosis lung disease*. *Advanced Drug Delivery reviews*, 2002. **54**: p. 1359-1371.
18. Rowe, S.M., S. Miller, and E.J. Sorscher, *Mechanisms of Disease: Cystic Fibrosis*. *The New England Journal of Medicine*, 2005. **352**(19): p. 1992-2001.
19. Coakley, J., et al., *Sweat testing for cystic fibrosis: standards of performance in Australasia*. *Annals of Clinical Biochemistry*, 2009. **46**: p. 332-337.
20. Behm, K., *INNO-LiPA CF2*. *Australasian Biotechnology (backfiles)*, 1996. **6**(5).
21. *Gen-Probe Life Sciences*, www.tepnel.com/elucigene-cf4.asp, accessed 07-10-2009.
22. *OLA Cystic Fibrosis Assay*, www.abbottmolecular.com/CysticFibrosisGenotypingAssay_100303.aspx, accessed 07-10-2009.
23. Dequeker, E., et al., *Recommendations for quality improvement in genetic testing for cystic fibrosis European Concerted Action of Cystic Fibrosis*. *European Journal of Human Genetics*, 2000. **8**: p. S2-S24.
24. Marino, C.R., et al., *Localisation of the cystic fibrosis transmembrane conductance regulator in the pancreas*. *Journal of Clinical Investigation*, 1991. **88**: p. 712.
25. Quinton, P.M., *Physiological basis of Cystic Fibrosis: A Historical Perspective*. *Physiological Reviews*, 1999. **79**: p. 3-22.
26. Johnston, C., et al. *Vasoactive intestinal peptide and abnormal mucus accumulation in the small bowel of patients with cystic fibrosis*. in *Perspectives in Cystic Fibrosis: Proceedings of the Eighth Annual Congress on Cystic Fibrosis*. 1980.
27. Cohen, L.H., P.A. Di Sant'Agnes, and J. Friedlander, *Cystic fibrosis and pregnancy: a national survey*. *Lancet*, 1980. **2**: p. 842-844.
28. Oppenheimer, E.H. and J.R. Esterly, *Observations on cystic fibrosis of the pancreas. VI. The uterine cervix*. *J. Pediatr.*, 1970. **77**: p. 991-995.
29. Knowles, M.R. and R.C. Boucher, *Mucus clearance a a primary innate defence mechanism for mammalian airways*. *Journal of Clinical Investigation*, 2002. **109**: p. 571-577.
30. Seiler, M.P., et al., *Thixotropic solutions enhance viral-mediated gene transfer to airway epithelia*. *American Journal of Respiratory Cell and Molecular Biology*, 2002. **27**: p. 133-140.
31. Gilligan, P., *Microbiology of airway disease in patients with cystic fibrosis*. *Clinical Microbiology Reviews*, 1991. **4**: p. 35-51.
32. Bedrossian, C., et al., *The lung in cystic fibrosis. A quantitative study including prevalence of pathological findings among different age groups*. *Human Pathology*, 1976. **7**: p. 195-204.

33. Davies, J.C. and E. Alton, *Monitoring Respiratory Disease Severity in Cystic Fibrosis*. *Respiratory Care*, 2009. **54**(5): p. 606-617.
34. Stutts, M.J., et al., *CFTR as a cAMP-dependant regulator of sodium channels*. *Science*, 1995. **269**: p. 847-850.
35. Lu, C., et al., *CFTR stabilizes ENaC at the plasma membrane*. *Journal of Cystic Fibrosis*, 2007. **6**: p. 419-422.
36. Boucher, R.C., et al., *Na⁺ transport in cystic fibrosis respiratory epithelia. Abnormal basal rate and response to adenylate cyclase activation*. *Journal of Clinical Investigation*, 1986. **78**: p. 1245-1252.
37. Willumson, N.J. and R.C. Boucher, *Sodium transport and intracellular sodium activity in cultured human nasal epithelium*. *Am. J. Physiol.*, 1991. **261**: p. C319-C331.
38. Willumson, N.J. and R.C. Boucher, *Transcellular sodium transport in cultured cystic fibrosis human nasal epithelium*. *Am. J. Physiol.*, 1991. **261**: p. C332-C341.
39. Jiang, C., et al., *Altered fluid transport across airway epithelium in cystic fibrosis*. *Science*, 1993. **262**: p. 424-427.
40. Matsui, H., et al., *Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease*. *Cell*, 1998. **95**: p. 1005-1015.
41. Tarran, R., et al., *The CF salt controversy: In vivo observations and therapeutic approaches*. *Molecular Cell*, 2001. **8**: p. 149-158.
42. Cowley, E.G., K, et al., *Airway surface liquid composition in mice*. *Respiratory Research*, 2001. **2**: p. 68577.
43. Knowles, M.R., et al., *Ion composition of airway surface liquid of patients with cystic fibrosis as compared with normal and disease-control subjects*. *Journal of Clinical Investigation*, 1997. **100**(10): p. 2588-2595.
44. Landry, J. and D. Eidelman, *Airway surface liquid. End of the controversy?* *Journal of General Physiology*, 2001. **117**(5): p. 419-422.
45. Regnis, J., et al., *Mucociliary clearance in patients with cystic fibrosis and normal subjects*. *American Journal of Respiratory and Critical Care Medicine*, 1994. **150**: p. 66-71.
46. Tarran, R., et al., *Normal and Cystic Fibrosis Airway Surface Liquid Homeostasis: The effects of phasic shear stress and viral infections*. *Journal of Biological Chemistry*, 2005. **280**.
47. Levy, H., et al., *Inflammatory markers of lung disease in Adult patients with cystic fibrosis*. *Paediatric Pulmonology*, 2007. **42**: p. 256-262.

48. Chan, H.C., J. Goldstein, and D. Nelson, *Alternative pathways for chloride activation in normal and cystic fibrosis airway epithelial cells*. American Journal of Physiology, 1992. **262**: p. C1273-C1283.
49. Burrows, E., K. Southern, and P.G. Noone, *Sodium channel blockers for cystic fibrosis*. Cochrane Database Syst Rev, 2006(3).
50. Zhou, Z., et al., *Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in BENC overexpressing mice*. American Journal of Respiratory and Critical Care Medicine, 2008. **178**: p. 1245-1256.
51. Wark, P. and V. McDonald, *Hypertonic Saline for cystic fibrosis*. Cochrane Database Systematic Reviews, 2008(4).
52. Fuchs, H.J., et al., *Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis*. New England Journal of Medicine, 1994. **331**: p. 637-642.
53. Glover, W., et al., *Effect of particle size of dry powder mannitol on the lung deposition in healthy volunteers*. International Journal of Pharmaceutics, 2008. **349**: p. 314-322.
54. Storey, S. and G. Wald, *Novel agents in cystic fibrosis*. Nature Reviews: Drug Discovery, 2008. **7**: p. 555-556.
55. *Inspire Pharmaceuticals. Press release 06 June 2008. Inspire Pharmaceuticals web site.*
56. Hirsh, A.J., et al., *Pharmacological Properties of 552-02, a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease*. Journal of Pharmacology And Experimental Therapeutics, 2008. **325**: p. 77-88.
57. Montier, T., et al., *Non-viral vectors in Cystic Fibrosis gene therapy: progress and challenges*. Trends In Biotechnology, 2004. **22**(11): p. 586-592.
58. Griesenbach, U., D.M. Geddes, and E. Alton, *Gene therapy progress and prospects: Cystic Fibrosis*. Gene Therapy, 2006. **13**(14): p. 1061-1067.
59. Farnen, S., et al., *Gene transfer of CFTR to airway epithelia: low levels of expression are sufficient to correct Cl⁻ transport and overexpression can generate basolateral CFTR*. American Journal of Physiology, Lung Cellular and Molecular Physiology, 2005. **289**: p. L1123-L1130.
60. Johnson, L., et al., *Efficiency of gene transfer for restoration of normal airway epithelial function in cystic fibrosis*. Nature Genetics, 1992. **2**: p. 21-25.
61. Zhang, L., et al., *CFTR Delivery to 25% of Surface Epithelial Cells Restores Normal Rates of Mucus Transport to Human Cystic Fibrosis Airway Epithelium*. PLOS Biology, 2009. **7**(7).
62. Rang, H.P., et al., *Pharmacology*. 5 ed. 2003: Churchill Livingstone. 739.

63. Lee, T.W.R., D.A. Matthews, and E.G. Blair, *Novel molecular approaches to cystic fibrosis gene therapy*. Biochemical Journal, 2005. **387 (Pt 1)**: p. 1-15.
64. Alton, E., et al., *Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial*. The Lancet, 1999. **353**: p. 947-954.
65. Flotte, T.R. and B. Laube, *Gene Therapy in Cystic Fibrosis*. Chest, 2001. **120(3)**: p. 124S-131S.
66. Robbins, P.D. and S.C. Ghivizzani, *Viral Vectors for Gene Therapy*. Pharmacol. Ther., 1998. **80(1)**: p. 35-47.
67. Klink, D., et al., *Nuclear translocation of lactosylated poly-L-lysine/cDNA complex in cystic fibrosis airway epithelial cells*. Molecular Therapy, 2001. **3(6)**: p. 831-841.
68. Fajac, I., et al., *Sugar-mediated uptake of glycosylated polylysines and gene transfer into normal and cystic fibrosis airway epithelial cells*. Human Gene Therapy, 1999. **10(3)**: p. 395-406.
69. Drumm, M.L., H.A. Pope, and W.H. Cliff, *Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer*. Cell, 1990. **62**: p. 1227-1233.
70. Grubb, B., R. Pickles, and H. Ye, *Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans*. Nature, 1994. **362**: p. 250-255.
71. Boucher, R.C., *Status of gene therapy for cystic fibrosis*. Journal of Clinical Investigation, 1999. **103**: p. 441-445.
72. Knowles, M.R., et al., *A controlled study of adenoviral-vector-mediated gene transfer in the nasal epithelium of patients with cystic fibrosis*. New England Journal of Medicine, 1995. **333**: p. 823-831.
73. Romanczuk, H., et al., *Modification of an adenoviral vector with biologically selected peptides: a novel strategy for gene delivery to cells of choice*. Gene Therapy, 1999. **10**: p. 2615-2626.
74. Kochanek, S., G. Schiedner, and C. Volpers, *High capacity, "gutless" adenoviral vectors*. Current Opinion in Molecular Therapeutics, 2001. **3**: p. 454-463.
75. Sakhuja, K., et al., *Optimization of the Generation and Propagation of Gutless Adenoviral Vectors*. Human Gene Therapy, 2003. **14**: p. 243-254.
76. Goldman, M., et al., *Transfer of the CFTR gene to the lung of non-human primates with E1-deleted, E2a-defective recombinant adenoviruses: A pre-clinical toxicology study*. Human Gene Therapy, 1995. **6(7)**: p. 839-851.
77. Flotte, T.R., et al., *Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector*. Proc. Natl. Acad. Sci, 1993. **90**: p. 10613-10617.

78. Flotte, T.R., et al., *Gene expression from adeno-associated virus vectors in airway epithelial cells*. American Journal of Respiratory Cell and Molecular Biology, 1992. **7**: p. 349-356.
79. Ding, W., et al., *Second-Strand Genome Conversion of Adeno-Associated Virus Type 2 (AAV-2) and AAV-5 Is Not Rate Limiting following Apical Infection of Polarized Human Airway Epithelia*. Journal of Virology, 2003. **77**(13): p. 7361-7366.
80. Griesenbach, U., et al., *Characterisation of Sendai virus carrying a GFP-CFTR fusion protein in vitro and in vivo*. Pediatric Pulmonology, 2005. **S28**: p. 269.
81. Griesenbach, U., et al., *Repeated administration of Sendai virus into lung*. Molecular Therapy, 2005. **11**: p. S327.
82. Griesenbach, U., et al., *Effect of tolerance induction to immunodominant T-cell epitopes of Sendai virus on gene expression following repeat administration to lung*. Gene Therapy, 2006. **13**: p. 449-456.
83. Cockrell, A. and T. Kafri, *HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go*. Current HIV Research, 2003. **1**: p. 419-439.
84. Stevenson, M., *Molecular Biology of Lentivirus-Mediated Gene Transfer*. Current Topics in Microbiology and Immunology, 2002. **261**: p. 1-23.
85. Trono, D., *HIV accessory proteins: Leading roles for the supporting cast*. Cell, 1995. **82**: p. 189-192.
86. Maddon, P.J., et al., *HIV infection does not require endocytosis of its receptor, CD4*. Cell, 1988. **54**: p. 865-874.
87. Klimatcheva, E., J.D. Rosenblatt, and V. Planelles, *Lentiviral Vectors and Gene Therapy*. Frontiers in Bioscience, 1999. **4**: p. 481-496.
88. Naldini, L., et al., *In vivo gene delivery and stable transduction of non dividing cells by a lentiviral vector*. Science, 1996. **272**(5259): p. 263-267.
89. Dull, T., et al., *A third-generation lentivirus vector with a conditional packaging system*. Journal of Virology, 1998. **72**(11): p. 8463-8471.
90. Verhoeven, E. and F.-L. Cosset, *Surface engineering of lentiviral vectors*. Journal of Gene Medicine, 2004. **6**(suppl 1): p. S83-94.
91. Medina, M.F., et al., *Lentiviral Vectors Pseudotyped with Minimal Filovirus Envelopes Increased Gene Transfer in Murine Lung*. Molecular Therapy, 2003. **8**(5).
92. Miyoshi, H., et al., *Stable and efficient gene transfer into the retina using an HIV-based lentiviral system*. Proc. Natl. Acad. Sci, 1997. **94**: p. 10319-10323.

93. Limberis, M., et al., *Recovery of Airway Cystic Fibrosis Transmembrane Conductance Regulator Function in Mice with Cystic Fibrosis after Single-Dose Lentivirus-Mediated Gene Transfer*. Human Gene Therapy, 2002. **13**: p. 1961-1970.
94. Blomer, U., et al., *Highly Efficient and Sustained Gene Transfer in Adult Neurons with a Lentivirus Vector*. Journal of Virology, 1997. **71**(9): p. 6641-6649.
95. Follenzi, A., et al., *Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences*. Nature Genetics, 2000. **25**: p. 217-222.
96. Johnson, L.G., et al., *Pseudotyped human lentiviral vector-mediated gene transfer to airway epithelia in vivo*. Gene Therapy, 2000. **7**(7): p. 568-574.
97. Zabner, J., J.A. Couture, and R.J. Gregory, *Adenovirus-mediated gene transfer transiently corrects the chloride transport defect in nasal epithelia of patients with cystic fibrosis*. Cell, 1993. **75**: p. 207-216.
98. Crystal, R.G., N.G. McElvaney, and M.A. Rosenfeld, *Administration of an adenovirus containing the human CFTR cDNA to the respiratory tract of individuals with cystic fibrosis*. Nat. Genet., 1994. **8**: p. 42-51.
99. Hay, J., et al., *Modification of nasal epithelial potential differences of individuals with cystic fibrosis consequent to local administration of a normal CFTR cDNA adenovirus gene transfer vector*. Human Gene Therapy, 1995. **6**(11): p. 1487-1496.
100. Zabner, J., et al., *Repeat Administration of an Adenovirus Vector Encoding Cystic Fibrosis Transmembrane Conductance Regulator to the Nasal Epithelium of Patients with Cystic Fibrosis*. Journal of Clinical Investigation, 1996. **97**(6): p. 1504-1511.
101. Wagner, J., et al., *A phase II, Double-Blind, Randomized, Placebo-Controlled Clinical Trial of tgAAVCF Using Maxillary Sinus Delivery in Patients with Cystic Fibrosis with Antrostomies*. Human Gene Therapy, 2002. **13**(11): p. 1349-1359.
102. Moss, R., *Gene therapy for cystic fibrosis- The rise and fall of a viral vector*. US Respiratory Disease, 2006(1).
103. Koldej, R., et al., *Optimisation of a multipartite human immunodeficiency virus based vector system; control of virus infectivity and large scale production*. The Journal of Gene Medicine, 2005. **7**: p. E-pub.
104. Couffinhal, T., et al., *Histochemical Staining Following LacZ Gene Transfer Underestimates Transfection Efficiency*. Human Gene Therapy, 1997. **8**: p. 929-934.
105. Anson, D.S. and M. Limberis, *An improved B-galactosidase reporter gene*. Journal of Biotechnology, 2004. **108**: p. 17-30.

106. Zhang, B., et al., *The significance of controlled conditions in lentiviral vector titration and in the use of multiplicity of infection (MOI) for predicting gene transfer events*. Genetic Vaccines and Therapy, 2004. **2**: p. 6-16.
107. Fuller, M. and D. Anson, *Helper Plasmids for Production of HIV-1-Derived Vectors*. Human Gene Therapy, 2001. **12**: p. 2081-2093.
108. Hacein-Bey, S., et al., *Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy*. New England Journal of Medicine, 2002. **346**: p. 1185-1193.
109. Cavazzana-Calvo, M., et al., *Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease*. Science, 2000. **288**: p. 669-672.
110. Hacein-Bey-Abina, S., et al., *LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1*. Science, 2003. **302**(415-419).
111. Hacein-Bey-Abina, S., et al., *A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency*. New England Journal of Medicine, 2003. **348**: p. 255-256.
112. Hacein-Bey-Abina, S., et al., *Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1*. Journal of Clinical Investigation, 2008. **118**: p. 3132-3142.
113. Deichmann, A., et al., *Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy*. Journal of Clinical Investigation, 2007. **117**: p. 2225-2232.
114. Howe, S., et al., *Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients*. Journal of Clinical Investigation, 2008. **118**: p. 3143-3150.
115. Pickles, R., et al., *Retargeting the coxsackievirus and adenovirus receptor to the apical surface of polarized epithelial cells reveals the glycocalyx as a barrier to adenovirus-mediated gene transfer*. Journal of Virology, 2000. **74**: p. 6050-6057.
116. Sanders, N., et al., *Cystic fibrosis sputum: a barrier to the transport of nanospheres*. American Journal of Respiratory Critical Care Medicine, 2000. **162**: p. 1905-1911.
117. Wang, G., et al., *Increasing epithelial tight junction permeability enhances gene transfer to airway epithelia in vivo*. American Journal of Respiratory Cell and Molecular Biology, 2000. **22**: p. 129-138.
118. Chu, Q., et al., *EGTA enhancement of adenovirus-mediated gene transfer to mouse tracheal epithelium in vivo*. Human Gene Therapy, 2001. **12**: p. 455-467.
119. Parsons, D., et al., *Enhanced In Vivo Airway Gene Transfer via Transient Modification of Host Barrier Properties with a Surface-Active Agent*. Human Gene Therapy, 1998. **9**: p. 2661-2672.

120. Man, Y., et al., *Loss of epithelial integrity resulting from E-cadherin dysfunction predisposes airway epithelial cells to adenoviral infection*. American Journal of Respiratory Cell and Molecular Biology, 2000. **23**: p. 610-617.
121. Everett, R., et al., *Specific modulation of airway epithelial tight junctions by apical application of an occludin peptide*. Molecular Pharmacology, 2006. **69**(2): p. 492-500.
122. Sinn, P.L., et al., *Persistent Gene Expression in Mouse Nasal Epithelia following Feline Immunodeficiency Virus-Based Vector Gene Transfer*. Journal of Virology, 2005. **79**(20): p. 12818-12827.
123. Sinn, P.L., et al., *Viscoelastic Gel Formulations Enhance Airway Epithelial Gene Transfer with Viral Vectors*. American Journal of Respiratory Cell and Molecular Biology, 2005. **32**: p. 404-410.
124. Wu, T.-L. and H.C. Ertl, *Immune barriers to successful gene therapy*. Cell, 2008.
125. Wu, T.-L. and H.C. Ertl, *Immune barriers to successful gene therapy*. Trends in Molecular Medicine, 2009. **15**(1): p. 32-39.
126. Norbury, C., et al., *CD8+ T cell cross-priming via transfer of proteasome substrates*. Science, 2004. **304**: p. 1318-1321.
127. Hensley, S.E., et al., *Dendritic Cell Maturation, but Not CD8+ T Cell Induction, Is Dependent on Type I IFN Signaling during Vaccination with Adenovirus Vectors*. Journal of Immunology, 2005. **175**: p. 6032-6041.
128. Jooss, K. and N. Chirmule, *Immunity to Adenovirus and Adeno-associated Viral Vectors: Implications for Gene Therapy*. Gene Therapy, 2003. **7**: p. 955-963.
129. Yang, Y., et al., *Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo*. Gene Therapy, 1996. **3**: p. 137-144.
130. Lin, S.-W., et al., *Recombinant adeno associated virus vectors induce functionally impaired transgene product-specific CD8+ T cells in mice*. Journal of Clinical Investigation, 2007. **117**: p. 3958-3970.
131. Mingozi, F., et al., *CD8+ T-cell responses to adeno-associated virus capsid in humans*. Nature Medicine, 2007. **13**: p. 419-422.
132. Epstein, A., et al., *HSV-1-derived recombinant and amplicon vectors for gene transfer and gene therapy*. Current Gene Therapy, 2005. **6**: p. 215-226.
133. Brown, B.S., G, et al., *In vivo administration of lentivirus vectors triggers a type 1 interferon response that restricts hepatocyte gene transfer and promotes vector clearance*. Blood, 2007. **109**: p. 2797-2805.

134. Follenzi, A., L. Santambrogio, and A. Annoni, *Immune responses to lentiviral vectors*. Current Gene Therapy, 2007. **7**: p. 306-315.
135. Akira, S., S. Uematsu, and O. Takeuchi, *Pathogen recognition and innate immunity*. Cell, 2006. **124**: p. 783-801.
136. Bowie, A. and L.A. O'Neill, *The interleukin-1 receptor/Toll-like receptor superfamily: Signal generators for pro-inflammatory interleukins and microbial products*. Journal of Leukocyte Biology, 2000. **67**: p. 508-514.
137. Kawai, T. and S. Akira, *Innate immune recognition of viral infection*. Nature Immunology, 2006. **7**: p. 131-137.
138. Iwasaki, A. and R. Medzhitov, *Toll-like receptor control of the adaptive immune responses*. Nature Immunology, 2004. **5**: p. 987-995.
139. Theofilopoulos, A.N., et al., *Type I interferons (α/β) in immunity and autoimmunity*. Annual Review Immunology, 2005. **23**: p. 307-336.
140. Turelli, P., et al., *Cytoplasmic Recruitment of INI1 and PML on Incoming HIV Preintegration Complexes: Interference with Early Steps of Viral Replication*. Molecular Cell, 2001. **7**(1245-1254).
141. Hamamoto, T., et al., *Leptomycins A and B, new antifungal antibiotics. I. Taxonomy of the producing strain and their fermentation, purification and characterisation*. Journal of Antibiot., 1983. **36**: p. 646-650.
142. Hamamoto, T., H. Seto, and T. Beppu, *Leptomycins A and B, new antifungal antibiotics. II. Structure elucidation*. Journal of Antibiot., 1983. **36**: p. 646-650.
143. Hamamoto, T., T. Uozumi, and T. Beppu, *Leptomycins A and B, new antifungal antibiotics. III. Mode of action of Leptomycin B on Schizosacharomyces pombe*. Journal of Antibiot., 1985. **38**: p. 1573-1580.
144. Komiyama, K., et al., *Structural study of a new antitumor antibiotic, Kazusamycin*. Journal of Antibiot., 1985. **38**: p. 224-230.
145. Wolff, B., J.-J. Sanglier, and Y. Wang, *Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA*. Chemistry and Biology, 1997. **4**: p. 139-147.
146. Sakamoto, K., *Ubiquitin-dependant proteolysis: its role in human diseases and the design of therapeutic strategies*. Molecular Genetics and Metabolism, 2002. **77**: p. 44-56.
147. Dunlop, R., K. Rodgers, and R. Dean, *Recent developments in the intracellular degradation of oxidised proteins*. Free Radical Biology and Medicine, 2002. **33**: p. 894-906.

148. Carrard, G., et al., *Impairment of proteasome structure and function in aging*. International Journal of Biochemistry and Cell Biology, 2002. **34**: p. 1461-1474.
149. Elliott, P.J. and J.S. Ross, *The Proteasome: A new target for novel drug therapies*. American Journal of Clinical Pathology, 2001. **116**: p. 637-646.
150. Kim, J., C.-P. Chen, and K. Rice, *The proteasome metabolizes peptide-mediated nonviral gene delivery systems*. Gene Therapy, 2005. **12**: p. 1581-1590.
151. Liu, D. and J. Knapp, *Hydrodynamics-based gene delivery*. Current Opinion in Molecular Therapeutics, 2001. **3**: p. 192-197.
152. Griesenbach, U., et al., *The role of doxorubicin in non-viral gene transfer in the lung*. Biomaterials, 2009. **10**: p. 1971-1977.
153. Duan, D., et al., *Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus*. Journal of Clinical Investigation, 2000. **105**: p. 1573-1587.
154. Glaumann, H. and F. Ballard, *Lysosomes: Their role in protein breakdown*. 1987: Academic Press.
155. Figueiredo-Pereira, M., et al., *The anti-tumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20S proteasome*. Journal of Biological Chemistry, 1996. **271**: p. 16455-16459.
156. Cummings, J., et al., *The molecular pharmacology of doxorubicin in vivo*. European Journal of Cancer, 1991. **27**: p. 532-535.
157. Tewey, K., et al., *Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II*. Science, 1984. **226**: p. 466-468.
158. Keizer, H.P., HM, G. Schuurhuis, and H. Joenje, *Doxorubicin (adriamycin) a critical review of free radical-dependant mechanisms of cytotoxicity*. Pharmacol. Ther., 1990. **47**: p. 219-231.
159. Muller, I., D. Niethammer, and G. Bruchelt, *Athracycline-derived chemotherapeutics in apoptosis and free radical cytotoxicity*. International Journal of Molecular Medicine, 1998. **1**: p. 491-494.
160. Singar, P. and N. Iliskovic, *Doxorubicin-induced cardiomyopathy*. New England Journal of Medicine, 1998. **339**: p. 900-905.
161. Kim, K., et al., *Doxorubicin Enhances the Expression of Transgene Under Control of the CMV Promoter in Anaplastic Thyroid Carcinoma Cells*. The Journal of Nuclear Medicine, 2007. **48**(9): p. 1553-1561.
162. Yan, Z., et al., *Distinct Classes of Proteasome-Modulating Agents Cooperatively Augment Recombinant Adeno-Associated Virus Type 2 and Type 5-Mediated Transduction from the Apical Surfaces of Human Airway Epithelia*. Journal of Virology, 2004. **78**(6): p. 2863-2874.

163. Schwartz, O., et al., *Antiviral activity of the proteasome on incoming human immunodeficiency virus type 1*. Journal of Virology, 1998. **72**(5): p. 3845-3850.
164. Okiyoneda, T., et al., *Bafilomycin A1-sensitive pathway is required for the maturation of cystic fibrosis transmembrane conductance regulator*. Biochemica et Biophysica Acta, 2006. **1763**: p. 1017-1023.
165. Wei, B.L., et al., *Inhibition of Lysosome and Proteasome Function Enhances Human Immunodeficiency Virus Type 1 Infection*. JOURNAL OF VIROLOGY,, 2005. **79**(9): p. 5705–5712.
166. Fredericksen, B.L., et al., *Inhibition of Endosomal/Lysosomal Degradation Increases the Infectivity of Human Immunodeficiency Virus*. Journal of Virology, 2002: p. 11440-11446.
167. Virella-Lowell, I., et al., *Inhibition of recombinant adeno-associated virus (rAAV) transduction by bronchial secretions fro cystic fibrosis patients*. Gene Therapy, 2000. **7**: p. 1783-1789.
168. Perricone, M., et al., *Inhibitory effect of cystic fibrosis sputum on adenovirus-mediated gene transfer in cultured epithelial cells*. Human Gene Therapy, 2000. **11**: p. 1997-2008.
169. Snouwaert, J., et al., *An animal model for cystic fibrosis made by gene targeting*. Science, 1992. **257**: p. 1083-1088.
170. Davidson, D.J. and M. Rolfe, *Mouse models of cystic fibrosis*. Trends in Genetics, 2001. **17**(10): p. S29-S37.
171. Grubb, B. and R.C. Boucher, *Pathophysiology of Gene-Targeted Mouse Models for Cystic Fibrosis*. Physiological Reviews, 1999. **79**(1): p. 193-214.
172. Frizzell, R.A. and J.M. Pilewski, *Finally, mice with CF lung disease*. Nature Medicine, 2004. **10**(5): p. 452-454.
173. Griesenbach, U., et al., *Limitations of the murine nose in the development of non-viral airway gene transfer*. American Journal of Respiratory Cell and Molecular Biology, 2009. **Epub ahead of print**.
174. Mall, M., et al., *Increased airway epithelial Na⁺ absorption produces cystic fibrosis-like lung disease in mice*. Nature Medicine, 2004. **10**: p. 487-493.
175. Ibrahim, Z., et al., *Selected physiologic compatibilities and incompatibilities between human and porcine organ systems*. Xenotransplantation, 2006. **13**: p. 488.
176. Rogers, C.S., et al., *The porcine lung as a potential model for cystic fibrosis*. Am. J. Physiol. Lung Cell Mol. Physiol., 2008. **295**: p. L240-L263.
177. Rogers, C.S., et al., *Production of CFTR-null and CFTR-ΔF508 heterozygous pigs by adeno-associated virus-mediated gene targeting and somatic cell nuclear transfer* Journal of Clinical Investigation, 2008. **118**: p. 1571-1577.

178. Rogers, C.S., et al., *Disruption of the CFTR gene produces a model of Cystic Fibrosis in newborn pigs*. Science, 2008. **321**: p. 1837-1841.
179. Sun, X., et al., *Adeno-associated virus-targeted disruption of the CFTR gene in cloned ferrets* Journal of Clinical Investigation, 2008. **118**: p. 1578-1583.
180. Li, Z. and J.F. Engelhardt, *Progress toward generating a ferret model of cystic fibrosis by somatic cell nuclear transfer*. Reproductive Biology and Endocrinology, 2003. **1**(83).
181. Schuler, D., et al., *Basic protocol for transepithelial nasal potential difference measurements*. Journal of Cystic Fibrosis, 2004. **3**: p. 151-155.
182. Grubb, B., et al., *Ion transport across CF and normal murine olfactory and ciliated epithelium*. American Journal of Physiology- Cell Physiology, 2009. **296**: p. C1301-1309.
183. Nimjee, S., C. Rusconi, and B. Sullenger, *Aptamers: An emerging class of therapeutics*. Annual Review of Medicine, 2005. **56**: p. 555-583.
184. Drose, S. and K. Altendorf, *Bafilomycins and Concanamycins as inhibitors of V-ATPases and P-ATPases*. The Journal of Experimental Biology, 1997. **200**: p. 1-8.
185. Fackler, O.T. and B.M. Peterlin, *Endocytic entry of HIV-1*. Current Biology, 2000. **10**: p. 1005-1008.
186. Jennings, K., *Proteasome inhibition enhances AAV-mediated transgene expression in human synoviocytes in vitro and in vivo*. Molecular Therapy, 2005. **11**: p. 600-607.
187. Keeling, *Vacuolar H⁺-ATPases. Targets for drug discovery?* Ann N Y Acad Sci, 1997. **834**: p. 600-608.
188. Orłowski, R., *Tumor growth inhibition induced in a murine model of human Burkitt's lymphoma by a protease inhibitor*. Cancer Research, 1998. **58**: p. 4342-4348.
189. Mattiske, K., *Towards Gene Therapy for Cystic Fibrosis- Achieving high level in vivo transduction of airway epithelium: Comparison of VSV-G and GP64 pseudotyped lentiviral vectors*, in *Pharmacy and Medical Sciences*. 2005, University of South Australia.
190. Dorin, J.R., *Progress in respiratory research*, in *Cystic Fibrosis in the 21st century*, A. Bush, et al., Editors. 2006, Karger: London. p. 84-92.
191. Grubb, B., A.M. Paradiso, and R.C. Boucher, *Anomalies in ion transport in cf mouse tracheal epithelium*. American Journal of Physiology, 1994. **267**: p. C293-C300.
192. Grubb, B., et al., *Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans*. Nature, 2002. **371**: p. 802-806.
193. Delaney, S., et al., *Cystic fibrosis mice carrying the missense mutation G551D replicate human genotype-phenotype correlations*. The EMBO Journal, 1996. **15**(5): p. 955-963.

194. Colledge, W., et al., *Generation and characterisation of a delta F508 cystic fibrosis mouse model*. Nature Genetics, 1995. **10**: p. 445-452.
195. Grubb, B. and S. Gabriel, *Intestinal physiology and pathology in gene-targeted mouse models of cystic fibrosis*. American Journal of Physiology, 1997. **273**: p. G258-G266.
196. Grubb, B., *Ion transport across the jejunum in normal and cystic fibrosis mice*. American Journal of Physiology, 1995. **31**: p. G505-G513.
197. Griesenbach, U., et al., *Validation of Nasal Potential Difference Measurements in Gut-Corrected CF Knockout Mice*. American Journal of Respiratory Cell and Molecular Biology, 2008. **39**: p. 490-496.
198. Zhou, L., et al., *Correction of Lethal Intestinal Defect in a Mouse Model of Cystic Fibrosis by Human CFTR*. Science, 1994. **266**: p. 1705-1708.
199. Hodges, C., M. Palmert, and M. Drumm, *Infertility in females with cystic fibrosis is multifactorial: Evidence from mouse models*. Endocrinology, 2008. **149**(6): p. 2790-2797.
200. Bunka, D. and P. Stockley, *Aptamers come of age-at last*. Nat Rev Microbiol, 2006. **4**(8): p. 588-596.
201. Kensch, O., et al., *HIV-1 reverse transcriptase/pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity*. The Journal of Biological Chemistry, 2000.
202. Tuerk, C. and L. Gold, *Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA-polymerase*. Science, 1990. **249**: p. 505-510.
203. Stoltenburg, R., C. Reinemann, and B. Strehlitz, *SELEX- A (r)evolutionary method to generate high-affinity nucleic acid ligands*. Biomolecular Engineering, 2007. **24**: p. 381-403.
204. Trapnell, B., et al., *Expression of the cystic fibrosis transmembrane conductance regulator gene in the respiratory tract of normal individuals and individuals with cystic fibrosis*. Proc Natl Acad Sci U S A, 1991. **88**(15): p. 6565-6569.
205. Chu, C., et al., *Extensive posttranscriptional deletion of the coding sequences for part of nucleotide-binding fold 1 in respiratory epithelial mRNA transcripts of the cystic fibrosis transmembrane conductance regulator gene is not associated with the clinical manifestations of cystic fibrosis*. Journal of Clinical Investigation, 1992. **90**: p. 785-790.
206. Dorin, J., et al., *A demonstration using mouse models that successful gene therapy for cystic fibrosis requires only partial gene correction*. Gene Therapy, 1996. **3**: p. 797-801.
207. Hahm, S., et al., *Construction of retroviral vectors with enhanced efficiency of transgene expression*. Journal of Virology Methods, 2004. **121**: p. 127-136.

208. Kung, S., D. An, and I. Chen, *A murine leukemia virus (MuLV) long terminal repeat derived from rhesus macaques in the context of a lentivirus vector and MuLV gag dequence results in high-level gene expression in human T lymphocytes*. *Journal of Virology*, 2000. **74**: p. 3668-3681.
209. Malik, P., et al., *Retroviral mediated expression in human myelomonocytic cells: a comparison of hematopoietic cell promoters to viral promoters*. *Blood*, 1995. **86**: p. 2993-3005.
210. Jiang, C., et al., *Ability of adenovirus vectors containing different CFTR transcriptional cassettes to correct ion transport defects in CF cells*. *Am J Physiol Lung Cell Mol Physiol*, 1996. **271**: p. L527-L537.
211. Yew, N., et al., *Optimization of plasmid vectors for high-level expression in lung epithelial cells*. *Human Gene Therapy*, 1997. **8**: p. 575-584.
212. Zabner, J., et al., *Adenovirus-mediated generation of cAMP-stimulated Cl⁻ transport in cystic fibrosis airway epithelia in vitro: effect of promoter and administration method*. *Gene Therapy*, 1996. **3**: p. 458-465.
213. Stutts, M.J., et al., *Functional consequences of heterologous expression of the cystic fibrosis transmembrane conductance regulator in fibroblasts*. *J Biol Chem*, 1993. **268**: p. 20653-20658.
214. Schiavi, S., et al., *Biosynthetic and growth abnormalities are associated with high-level expression of CFTR in heterologous cells*. *Am J Physiol Cell Physiol*, 1996. **270**: p. C341-C351.
215. Wang, G., et al., *Feline immunodeficiency virus vectors persistently transduce nondividing airway epithelia and correct the cystic fibrosis defect*. *Journal of Clinical Investigation*, 1999. **104**: p. R55-R62.
216. Chow, Y., et al., *Development fo an epithelium-specific expression cassette with human DNA regulatory elements for transgene expression in lung airways*. *Proceedings of the National Academy of Sciences*, 1997. **94**: p. 14695-14700.
217. Mitomo, K., et al., *Toward Gene Therapy for Cystic Fibrosis Using a Lentivirus Pseudotyped with Sendai Virus Envelopes*. *Molecular Therapy*, 2010. **Advanced Copy**.
218. Stocker, A., et al., *Single-dose lentiviral gene transfer for lifetime airway gene expression*. *Journal of Gene Medicine*, 2009. **11**(10): p. 861-867.
219. Bennett, W., et al., *Targeting delivery of aerosols to different lung regions*. *Journal of Aerosol Medicine*, 2002. **15**: p. 179-188.
220. Lentz, Y., T. Anchoroquy, and C. Lengsfeld, *Rationale for the selection of an aerosol delivery system for gene delivery*. *Journal of Aerosol Medicine*, 2006. **19**(3): p. 372-384.
221. Fink, J., *Metered-dose inhalers, dry powder inhalers, and transitions*. *Respiratory Care*, 2000. **45**: p. 623-635.

222. Geller, D.E., *New liquid aerosol generation devices: systems that force pressurized liquids through nozzles*. *Respiratory Care*, 2002. **47**: p. 1392-1404.
223. Terzano, C., *Pressurized metered dose inhalers and add-on devices*. *Pulmonary Pharmacology and Therapeutics*, 2001. **14**: p. 351-366.
224. Sacchetti, M. and M. Van Oort, *Spray-drying and supercritical fluid particle generation techniques*, in *Inhalation Aerosols: Physical and Biological Basis for Therapy*, A. Hickey, Editor. 1996, Marcel Dekker: New York. p. 337-384.
225. Finlay, W., *The Mechanics of Inhaled Pharmaceutical Aerosols: An introduction*. Academic Press, San Diego, 2001.
226. Tang, K. and A. Gomez, *generation by electrospray of monodisperse water droplets for targeted drug-delivery by inhalation*. *Journal of Aerosol Science*, 1994. **25**: p. 1237-1249.
227. Rubin, B.K., *Other medications for aerosol delivery*. *Paediatric Respiratory Reviews*, 2006. **75**: p. S76-S79.